<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01650168</url>
  </required_header>
  <id_info>
    <org_study_id>ZEG2013_08</org_study_id>
    <nct_id>NCT01650168</nct_id>
  </id_info>
  <brief_title>Prospective Controlled Cohort Study on the Safety of a Monophasic Oral Contraceptive Containing Nomegestrol Acetate (2.5mg) and 17ß-estradiol (1.5mg)</brief_title>
  <acronym>PRO-E2</acronym>
  <official_title>Prospective Controlled Cohort Study on the Safety of a Monophasic Oral Contraceptive Containing Nomegestrol Acetate (2.5mg) and 17ß-estradiol (1.5mg)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center for Epidemiology and Health Research, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Theramex</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Center for Epidemiology and Health Research, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compares the risks of short- and long-term use of NOMAC-E2 (containing a fixed&#xD;
      dose of nomegestrol acetate and estradiol) compared with levonorgestrel-containing combined&#xD;
      oral contraceptives (COC-LNG) in a study population representative of the actual users of the&#xD;
      individual preparations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NOMAC-E2 is a novel monophasic oral contraceptive containing a fixed dose of nomegestrol&#xD;
      acetate (2.5mg) and 17ß-estradiol (1.5mg) which is taken for 24 days followed by 4 days of&#xD;
      placebo. The most relevant adverse clinical outcome that has been linked to the use of COCs&#xD;
      is venous thromboembolism (VTE). Data from randomized clinical trials did not show any&#xD;
      serious health concerns for NOMAC-E2. However, the statistical power to detect rare adverse&#xD;
      events is limited in these studies.&#xD;
&#xD;
      PRO-E2 is a large, prospective, controlled, long-term active surveillance study to&#xD;
      investigate the safety of NOMAC-E2 with regard to the outcomes of interest. This study&#xD;
      follows the European Active Surveillance (EURAS) design methodology with some modifications&#xD;
      due to country- and product-specific characteristics. The outcomes of interest will be&#xD;
      validated via the attending physicians. A multi-faceted follow-up procedure will ensure a low&#xD;
      loss to follow-up rate. This study will involve women from Europe and Australia who will be&#xD;
      followed for up to 2 years. Data analysis will include multivariable techniques such as Cox&#xD;
      regression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Venous thromboembolisms (VTE)</measure>
    <time_frame>Within 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial thromboembolisms (ATE)</measure>
    <time_frame>Within 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depressive disorders</measure>
    <time_frame>Within 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholelithiasis</measure>
    <time_frame>Within 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory bowel disease</measure>
    <time_frame>Within 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short- and long-term fertility</measure>
    <time_frame>Within 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug utilization pattern</measure>
    <time_frame>Within 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcomes</measure>
    <time_frame>Within 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight change</measure>
    <time_frame>Within 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General hepatobiliary disorders</measure>
    <time_frame>Within 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acne</measure>
    <time_frame>Within 2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">101498</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>NOMAC-E2</arm_group_label>
    <description>New users of NOMAC-E2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LNG-COCs</arm_group_label>
    <description>New users of levonorgestrel-containing COCs</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Women using oral contraceptives&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  First ever user of a COC (&quot;starter&quot;)&#xD;
&#xD;
          -  User who restarts hormonal contraceptive use with a COC (same COC as before or a new&#xD;
             COC) after an intake break of at least two months (&quot;restarters&quot;)&#xD;
&#xD;
          -  Women willing to participate in the active surveillance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Women who do not understand the major aspects of the study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaas Heinemann, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Epidemiology and Health Research, Berlin, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Epidemiology and Health Research Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 13, 2012</study_first_submitted>
  <study_first_submitted_qc>July 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2012</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NOMAC-E2</keyword>
  <keyword>Nomegestrol acetate</keyword>
  <keyword>Estradiol</keyword>
  <keyword>Levonorgestrel</keyword>
  <keyword>Safety</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

